PainReform up on initiating late-stage study of lead drug candidate

PRF Technologies

14/03/2023 13:00

** Shares of Israeli drug developer PainReform Ltd  PRFX.O 
up 20% at $0.62 premarket
    ** Co initiates late-stage study of PRF-110, co's lead drug
candidate
    ** PRF-110 is an oil-based solution deposited directly into
the surgical wound to provide localized and extended
post-operative pain relief - PRFX
    ** Trial aims to evaluate the efficacy and safety of PRF-110
following bunionectomy, a surgical procedure that moves toes
back into the correct position - PRFX
    ** Stock down 48% in last 12 months

 (Reporting by Aditya Samal)
 ((Aditya.Samal@thomsonreuters.com;))